全體奇點糕嘔心瀝血嘔心瀝血嘔心瀝血打造的重磅音頻課程《醫學趨勢50講》終於上線了。我們一口氣幫你同步了全球醫學前沿領域最重磅的進展。只需500分鐘,讓你徹底搞懂最重磅的醫學前沿進展。
課程亮點如下:
1、全面:一網打盡最重磅的醫學前沿進展。
在這套《醫學趨勢50講》中,我們囊括了免疫治療、幹細胞、微生物、人工智慧、二代測序,抗癌新藥研發等15個重要的前沿領域,幫你將全球最頂尖的科研成果一舉收入囊中。
2、緊跟趨勢:幫你無縫同步全球認知。
奇點跨學科專業知識團隊,依靠強大的自有資料庫系統,每天跟蹤全球3000多本醫學與生命科學領域的重要期刊,實時把握醫學前沿科技最強勁的脈搏。和全球認知同步,你不需要費心費力,我們把全球脈動送到你的耳邊。
3、有趣易懂:不用絞盡腦汁,就能理解全球醫學頂尖難題。
醫學和生命科學領域的論文往往晦澀難懂,再加上語言的隔閡,導致很多人對此望而卻步。這一次,我們幫你把艱深晦澀的前沿學術調製成清新爽口的科學小品,讓你在享受科學之美的同時,輕輕鬆鬆理解醫學頂尖難題。和全球最聰明的大腦思考同樣的問題,你也可以。
長按識別下圖二維碼,即可購買這套超值的音頻課程。兩人拼團即可享有超值優惠價格。
為了進一步提升我們知識服務的品質,歡迎您添加奇點主編的微信,隨時交流課程感想。
參考資料:
[1]https://www.youtube.com/watch?v=ApXvIUPe24s
[2]https://www.ema.europa.eu/en/documents/product-information/biktarvy-epar-product-information_en.pdf
[3] Fanalesbelasio E, Raimondo M, Suligoi B, et al. HIV virology and pathogenetic mechanisms of infection: a brief overview[J]. Annali dell'Istituto Superiore di Sanità, 2010, 46(1): 5-14.
[4] Cihlar T, Fordyce M. Current status and prospects of HIV treatment.[J]. Current Opinion in Virology, 2016: 50-56.
[5] Choi E, Mallareddy J R, Lu D, et al. Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase[J]. Future Science OA, 2018, 4(9).
[6] Hazuda D J. HIV integrase as a target for antiretroviral therapy.[J]. Current Opinion in Hiv and Aids, 2012, 7(5): 383-389.
[7] Hazuda D J, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells[J]. Science, 2000, 287(5453): 646-650.
[8] Tsiang M, Jones G S, Goldsmith J, et al. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile[J]. Antimicrobial Agents and Chemotherapy, 2016, 60(12): 7086-7097
[9] De Boer M G, Den Berk G E, Van Holten N, et al. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice[J]. AIDS, 2016, 30(18): 2831-2834.
[10] Lazerwith SE, Cai R, Chen X, et al. Discovery of GS-9883, an HIV-1integrase strand transfer inhibitor (INSTI) with improved pharmacokinetics and in vitro resistance profile. ASM Microbe; Boston, MA, USA; June 16–20, 2016. 414 (abstr).
[11] Markham A. Bictegravir: First Global Approval.[J]. Drugs, 2018, 78(5): 601-606.
[12] Post F A, Yazdanpanah Y, Schembri G, et al. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial[J]. HIV clinical trials, 2017, 18(3): 135-140.
[13] Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial[J]. The Lancet, 2017, 390(10107): 2063-2072.
[14]https://www.gilead.com/news-and-press/press-room/press-releases/2018/6/european-commission-grants-marketing-authorization-for-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-the-treatment-of-hiv
[15] Saag M S, Benson C A, Gandhi R T, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society–USA Panel[J]. Jama, 2018, 320(4): 379-396.
[16]https://www.gilead.com/news-and-press/press-room/press-releases/2019/8/china-national-medical-products-administration-approves-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv1-infect
[17]https://www.gilead.com/news-and-press/press-room/press-releases/2019/11/gileads-biktarvy-maintained-high-efficacy-with-no-cases-of-treatment-emergent-resistance-through-three-years-in-phase-3-hiv-clinical-trials
[18]http://www.nhc.gov.cn/jkj/s3586/201911/c2388ce70bdd404ea6dfcd886591784d.shtml
本文作者 | WXY707